glp-1 fda approved for weight loss A big win Wegovy: drug semaglutide first in history to gain approval for reducing heart risks How Employers Can Optimize Benefits

Tirzepatide, sold as Mounjaro and Zepbound, is a dual GIP/GLP-1 medication that has gained popularity for weight loss and type 2 diabetes management

We need to do more about this

E.BurgoyneT.LyuZ.OquaA

reported that semaglutide accessed the brainstem, hypothalamus, and the dorsal half of the septal area, largely via small circumventricular organs, but it was not shown to cross the BBB [27]

Managing Side Effects Success with these medications often depends on proper management of side effects

Patients can expect to see significant weight loss within the first three months of beginning Semaglutide GLP-1 treatment, although individual results may vary